Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 7/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ILK | Q13418 | 1/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4729268 | 0.90 | DYRK1A (0.56) | APPILKGAA | |
| SCHEMBL1982972 | 0.86 | APP (0.67) | APPCYP1A2CYP3A4CYP2C19ILK | |
| SCHEMBL229456 | 0.84 | APP (0.68) | APPCYP1A2CYP3A4CYP2C19ILK | |
| SCHEMBL1982303 | 0.81 | APP (0.62) | APPCYP1A2CYP3A4CYP2C19ILK | |
| SCHEMBL5086604 | 0.80 | APP (0.56) | APPILKALKGLAGAA | |
| SCHEMBL1977100 | 0.80 | APP (1.00) | APPCYP1A2CYP3A4CYP2C19GLA | |
| SCHEMBL12974045 | 0.80 | APP (1.00) | APPCYP1A2CYP3A4CYP2C19GLA | |
| SCHEMBL5756089 | 0.80 | APP (0.62) | APPCYP1A2CYP3A4CYP2C19ILK | |
| SCHEMBL793099 | 0.79 | APP (0.61) | APPCYP1A2CYP3A4CYP2C19ILK | |
| SCHEMBL28798406 | 0.79 | APP (0.61) | APPCYP1A2CYP3A4CYP2C19ILK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0721336-B1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RES CAMPAIGN TECH (GB) | 1999-07-14 | — | — | EP | claimed |
| EP-0721336-A1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-07-17 | — | — | EP | claimed |
| WO-1995006469-A1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1995-03-09 | — | — | WO | claimed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| EP-0721336-B1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RES CAMPAIGN TECH (GB) | 1999-07-14 | — | — | EP | disclosed |
| US-5874431-A | ANTITUMOR AGENTS; BREAST CANCER | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-02-23 | — | — | US | disclosed |
| EP-0721336-A1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-07-17 | — | — | EP | disclosed |
| WO-1995006469-A1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | APP 24/4885CYP1A2 4587/4885CYP3A4 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.